Comparison of proportional hazard model and neural network models in a real data set of intensive care unit patients.

Stud Health Technol Inform

Department of Preventive Medicine, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan.

Published: June 2005

There has been increased interest in using neural network model (NNM) for prognosis tasks. However, the performance of NNM has seldom been compared with that of traditional statistical models such as proportional hazard model (PHM) in real data sets. We conducted a comparative study of PHM and two types of NNM, that is, aggregate single point model (ASPM) and multiple point model (MPM), using a real data set of intensive care unit patients. The three models were developed using the 70% training subset and their predictive accuracy were assessed using the 30% testing subset according to classification accuracy, area under receiver operating curve, and concordance index. Overall, the highest predictive accuracy was found in MPM, followed by PHM and ASPM. MPM is likely to have the potential ability to provide more accurate estimation of prognosis than PHM and ASPM

Download full-text PDF

Source

Publication Analysis

Top Keywords

real data
12
proportional hazard
8
hazard model
8
neural network
8
data set
8
set intensive
8
intensive care
8
care unit
8
unit patients
8
point model
8

Similar Publications

Background: Molnupiravir (MOV) is an orally bioavailable ribonucleoside with antiviral activity against all tested SARS-CoV-2 variants. We describe the demographic, clinical, and treatment characteristics of non-hospitalized Danish patients treated with MOV and their clinical outcomes following MOV initiation.

Method: Among all adults (>18 years) who received MOV between 16 December 2021 and 30 April 2022 in an outpatient setting in Denmark, we summarized their demographic and clinical characteristics at baseline and post-MOV outcomes using descriptive statistics.

View Article and Find Full Text PDF

Introduction: Prescribable digital health applications (DiGAs) present scalable solutions to improve patient self-management in rheumatology, however real-world evidence is scarce. Therefore, we aimed to assess the effectiveness, usage, and usability of DiGAs prescribed by rheumatologists, as well as patient satisfaction.

Methods: The DiGAReal registry includes adult patients with rheumatic conditions who received a DiGA prescription.

View Article and Find Full Text PDF

exon 14 ex14) skipping occurs in 3-4% of non-small-cell lung cancer (NSCLC) cases. Low frequency of this alteration necessitated open-label, single-arm trials to investigate MET inhibitors. Since broad MET biomarker testing was only recently introduced in many countries, there is a lack of historical real-world data from patients with ex14 skipping NSCLC receiving conventional therapies.

View Article and Find Full Text PDF

Nowcasting to Monitor Real-Time Mpox Trends During the 2022 Outbreak in New York City: Evaluation Using Reportable Disease Data Stratified by Race or Ethnicity.

Online J Public Health Inform

January 2025

Bureau of Communicable Disease, New York City Department of Health and Mental Hygiene, Long Island City, NY, United States.

Background: Applying nowcasting methods to partially accrued reportable disease data can help policymakers interpret recent epidemic trends despite data lags and quickly identify and remediate health inequities. During the 2022 mpox outbreak in New York City, we applied Nowcasting by Bayesian Smoothing (NobBS) to estimate recent cases, citywide and stratified by race or ethnicity (Black or African American, Hispanic or Latino, and White). However, in real time, it was unclear if the estimates were accurate.

View Article and Find Full Text PDF

To estimate time-to-progression milestones in people with amyotrophic lateral sclerosis (PALS) treated versus not treated with intravenous (IV) edaravone (Radicava IV, Mitsubishi Tanabe Pharma America [MTPA], hereafter "IV edaravone") in a real-world setting. IV edaravone is US FDA approved for the treatment of ALS and was shown in clinical trials to slow the rate of physical functional decline. This retrospective observational analysis included PALS continuously enrolled in Optum's Clinformatics Data Mart between 8 August 2017 and 31 December 2021.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!